Oral bioavailable ITRI-148 degrades androgen receptor variants and overcomes antiandrogen resistance in advanced prostate cancer.

Saved in:
Bibliographic Details
Title: Oral bioavailable ITRI-148 degrades androgen receptor variants and overcomes antiandrogen resistance in advanced prostate cancer.
Authors: Hung CL; Department of Preclinical Drug Discovery Technology, Biomedical Technology and Devices Research Labs, Industrial Technology Research Institute, Hsinchu 31040, Taiwan., Hsu WN; Department of Biochemistry and Molecular Biology, Chang Gung University, Taoyuan 33302, Taiwan., Wang TC; Graduate Institute of Biomedical Sciences, Chang Gung University, Taoyuan 33302, Taiwan., Chen WR; Department of Preclinical Drug Discovery Technology, Biomedical Technology and Devices Research Labs, Industrial Technology Research Institute, Hsinchu 31040, Taiwan., Chen YT; Department of Preclinical Drug Discovery Technology, Biomedical Technology and Devices Research Labs, Industrial Technology Research Institute, Hsinchu 31040, Taiwan., Kuo ZK; Department of Preclinical Drug Discovery Technology, Biomedical Technology and Devices Research Labs, Industrial Technology Research Institute, Hsinchu 31040, Taiwan., Hu TL; Department of Preclinical Drug Discovery Technology, Biomedical Technology and Devices Research Labs, Industrial Technology Research Institute, Hsinchu 31040, Taiwan., Lin YC; Department of Preclinical Drug Discovery Technology, Biomedical Technology and Devices Research Labs, Industrial Technology Research Institute, Hsinchu 31040, Taiwan., Yeh HH; Graduate Institute of Biomedical Sciences, Chang Gung University, Taoyuan 33302, Taiwan., Lin HC; Graduate Institute of Biomedical Sciences, Chang Gung University, Taoyuan 33302, Taiwan., Yu CJ; Graduate Institute of Biomedical Sciences, Chang Gung University, Taoyuan 33302, Taiwan; Department of Cell and Molecular Biology, Chang Gung University, Taoyuan 33302, Taiwan; Molecular Medicine Research Center, Chang Gung University, Taoyuan 33305, Taiwan; Department of Thoracic Medicine, Chang Gung Memorial Hospital at Linkou, Taoyuan 33305, Taiwan., Fu CW; Department of Preclinical Drug Discovery Technology, Biomedical Technology and Devices Research Labs, Industrial Technology Research Institute, Hsinchu 31040, Taiwan., Liu HH; Department of Preclinical Drug Discovery Technology, Biomedical Technology and Devices Research Labs, Industrial Technology Research Institute, Hsinchu 31040, Taiwan., Hsu HC; Division of Hematology-Oncology, Chang Gung Memorial Hospital at Linkou, Taoyuan 33305, Taiwan; School of Medicine, College of Medicine, Chang Gung University, Taoyuan 33305, Taiwan., Lin PH; School of Medicine, College of Medicine, Chang Gung University, Taoyuan 33305, Taiwan; Division of Urology, Department of Surgery, Chang Gung Memorial Hospital at Linkou, Taoyuan 33305, Taiwan., Pang ST; School of Medicine, College of Medicine, Chang Gung University, Taoyuan 33305, Taiwan; Division of Urology, Department of Surgery, Chang Gung Memorial Hospital at Linkou, Taoyuan 33305, Taiwan., Lai CH; Graduate Institute of Biomedical Sciences, Chang Gung University, Taoyuan 33302, Taiwan; Department of Microbiology and Immunology, Chang Gung University, Taoyuan 33302, Taiwan., Wang LY; Department of Biochemistry and Molecular Biology, Chang Gung University, Taoyuan 33302, Taiwan; Graduate Institute of Biomedical Sciences, Chang Gung University, Taoyuan 33302, Taiwan; Division of Hematology-Oncology, Chang Gung Memorial Hospital at Linkou, Taoyuan 33305, Taiwan. Electronic address: lywang@mail.cgu.edu.tw.
Source: Neoplasia (New York, N.Y.) [Neoplasia] 2026 Jan; Vol. 71, pp. 101253. Date of Electronic Publication: 2025 Nov 13.
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 100886622 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5586 (Electronic) Linking ISSN: 14765586 NLM ISO Abbreviation: Neoplasia Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1476-5586
DOI:10.1016/j.neo.2025.101253